


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
HSMN NewsFeed - 10 Jan 2019
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
HSMN NewsFeed - 4 Jan 2019
LifeX Announces Portfolio Company NeuBase Therapeutics To Merge with Ohr Pharmaceutical
LifeX Announces Portfolio Company NeuBase Therapeutics To Merge with Ohr Pharmaceutical
HSMN NewsFeed - 4 Jan 2019
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
HSMN NewsFeed - 20 Dec 2018
Kypha Secures $4M Series A Funding to Accelerate First-in-Class Diagnostic Platform Commercialization
Kypha Secures $4M Series A Funding to Accelerate First-in-Class Diagnostic Platform Commercialization
HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
HSMN NewsFeed - 18 Dec 2018
Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer
Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer
HSMN NewsFeed - 17 Dec 2018
Proteostasis Therapeutics Announces Global License Agreement with Genentech
Proteostasis Therapeutics Announces Global License Agreement with Genentech
HSMN NewsFeed - 14 Dec 2018
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
HSMN NewsFeed - 13 Dec 2018
Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET(TM) Immunotherapy Drug Candidates
Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET(TM) Immunotherapy Drug Candidates
HSMN NewsFeed - 12 Dec 2018
Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing
Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing
HSMN NewsFeed - 12 Dec 2018
Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets
Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets
HSMN NewsFeed - 11 Dec 2018
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
HSMN NewsFeed - 10 Dec 2018
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort(R) Topical Spray 0.25%
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort(R) Topical Spray 0.25%
HSMN NewsFeed - 10 Dec 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
HSMN NewsFeed - 6 Dec 2018
Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors
Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors
HSMN NewsFeed - 5 Dec 2018
Icagen enters into Collaboration to Develop and Commercialize Therapy for Neurological Diseases
Icagen enters into Collaboration to Develop and Commercialize Therapy for Neurological Diseases
HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
HSMN NewsFeed - 3 Dec 2018
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
HSMN NewsFeed - 30 Nov 2018
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
HSMN NewsFeed - 29 Nov 2018
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis
HSMN NewsFeed - 29 Nov 2018
Nuvo Pharmaceuticals(TM) Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
Nuvo Pharmaceuticals(TM) Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
HSMN NewsFeed - 29 Nov 2018
BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion
BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion
HSMN NewsFeed - 28 Nov 2018
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron(TM) from GE Healthcare
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron(TM) from GE Healthcare
HSMN NewsFeed - 28 Nov 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
